AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3372910
Drug: 2 units
RxNorm normalized name: Afrezza, 12 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 units of intravenous glucagon
Trial: 3372910
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of saline (placebo)
Trial: 27855097
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment at the original dose plus intravenous iron dextran 200 mg every 3 weeks (Q3W) for 15 weeks
Trial: 27855097
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment at the original dose plus intravenous iron dextran 100 mg, twice a week for 5 weeks
Trial: 27855097
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the EPO dose without preplanned iron supplementation
Trial: 22836063
Drug: Concomitant accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant accelerated boost (CB: once per day, 3 days per week, and twice per day, 2 days per week)
Trial: 20390354
Drug: Preoperative bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative bowel preparation (BP)
Trial: 20390354
Drug: Surgery without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery without bowel preparation (BP)
Trial: 16888454
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) supplementation (20 g.d(‐1) for 7 d then 5 g.d(‐1) for 4‐7 d)
Trial: 333852
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg nalbuphine
Trial: 333852
Drug: 0.14 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg nalbuphine
Trial: 333852
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg pentazocine
Trial: 333852
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg pentazocine
Trial: 6759060
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol (160 mg once daily)
Trial: 6759060
Drug: Sustained-release clonidine
RxNorm normalized name: clonidine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release clonidine (0.25 mg once daily)
Trial: 29343076
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin 40 mg daily for 1 day before to 3 days after contrast administration
Trial: 29343076
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose atorvastatin 10 mg daily for 1 day before to 3 days after contrast administration
Trial: 19028044
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg once in the morning for 7 days post-operation)
Trial: 19028044
Drug: Standard pre-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pre- and postoperative therapy (control group B)
Trial: 17574951
Drug: Neck muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck muscle endurance (NME) treatment for patients with NP
Trial: 17574951
Drug: Neck muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck muscle endurance (NME) treatment for patients with ACDF
Trial: 11933130
Drug: Pycnogenol (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (360 mg per day)
Trial: 11933130
Drug: Venostasin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venostasin (600 mg per day)
Trial: 9862573
Drug: Linomide 5
RxNorm normalized name: cupric oxide 1.5 MG / folic acid 0.5 MG / niacinamide 750 MG / zinc oxide 25 MG [Nicomide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide 5 mg or 10 mg p.o. daily for 2 weeks
Trial: 9862573
Drug: Alpha‐interferon added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha‐interferon added at 3 MU s.c. three times weekly, escalating by 3 MU per week up to 12 MU
Trial: 9862573
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Linomide and alpha‐interferon
Trial: 9862573
Drug: Linomide 5
RxNorm normalized name: cupric oxide 1.5 MG / folic acid 0.5 MG / niacinamide 750 MG / zinc oxide 25 MG [Nicomide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide 5 mg for 2 weeks
Trial: 28810837
Drug: Overall response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Overall response to treatment
Trial: 8770850
Drug: tissue plasminogen
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tissue plasminogen activator (t-PA) given in an accelerated dosing regimen
Trial: 11097130
Drug: No reperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No reperfusion therapy
Trial: 20551
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg BS 100‐141
Trial: 20551
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg BS 100‐141
Trial: 20551
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg BS 100‐141 (crossover study)
Trial: 20551
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg BS 100‐141 (crossover study)
Trial: 20551
Drug: 0.30 mg
RxNorm normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg clonidine (crossover study)
Trial: 19708803
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg three times daily (TID)
Trial: 17561929
Drug: levocetirizine 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levocetirizine 0.125 mg/kg
Trial: 11897984
Drug: High bronchodilator
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bronchodilator reversibility
Trial: 30929225
Drug: Medical exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical exercise therapy
Trial: 8582540
Drug: Darglitazone 25
RxNorm normalized name: alogliptin 25 MG / pioglitazone 30 MG [Oseni]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darglitazone 25 mg once a day for 14 days
Trial: 355602
Drug: Baclofen (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (mean dose 45 mg daily)
Trial: 31870811
Drug: Obese patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese patients (BMI ≥30 kg/m2) in the MSK immunotherapy cohort
Trial: 30741705
Drug: Cognitive orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive orientation to daily occupational performance (CO‐OP)
Trial: 25344807
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tenofovir/emtricitabine/rilpivirine
Trial: 24337447
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation (ASCT) after first-line therapy
Trial: 24337447
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation (ASCT) after second-line therapy
Trial: 29354913
Drug: Auricular plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular plaster therapy
Trial: 17717132
Drug: hsCRP >3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP >3 mg/L in unstable angina/non-ST-elevation myocardial infarction (NSTEMI)
Trial: 17717132
Drug: hsCRP >10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP >10 mg/L in STEMI
Trial: 9591496
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (2.5 mg)
Trial: 9591496
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (5 mg)
Trial: 9591496
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (10 mg)
Trial: 9591496
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (15 mg)
Trial: 7951368
Drug: Biken-Cam vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biken-Cam vaccine (5,000 TCID50/0.5 ml)
Trial: 7951368
Drug: Edmonston-Zagreb vaccine
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb vaccine with multiple puncture cylinder (7,000 TCID50/0.5 ml)
Trial: 7951368
Drug: Edmonston-Zagreb vaccine
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb vaccine with bifurcated needle (7,000 TCID50/0.5 ml)
Trial: 29791259
Drug: Free cessation
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free cessation aids (nicotine-replacement therapy or pharmacotherapy, with e-cigarettes if standard therapies failed)
Trial: 29791259
Drug: Free e-cigarettes
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Free e-cigarettes (without requirement that standard therapies had been tried)
Trial: 10364999
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 5 mg
Trial: 8254467
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral fluconazole once daily for 14 days
Trial: 8254467
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg clotrimazole five times daily for 14 days
Trial: 8254467
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral fluconazole once daily
Trial: 8254467
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg clotrimazole five times daily
Trial: 19857367
Drug: 48 g
RxNorm normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 g Resistant Starch (RS)
Trial: 21574983
Drug: Briakinumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Briakinumab (200 mg at weeks 0 and 4, followed by 100 mg at week 8)
Trial: 21574983
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg twice weekly at weeks 0-11)
Trial: 16941367
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV)
Trial: 12698776
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch (norelgestromin and ethinyl estradiol)
Trial: 18238962
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch
Trial: 7030901
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion (35 mEq/5h)
Trial: 1912107
Drug: Biperiden 2
RxNorm normalized name: biperiden 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 2 mg
Trial: 1912107
Drug: Biperiden 4
RxNorm normalized name: biperiden 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 4 mg
Trial: 31834098
Drug: Biperiden 2
RxNorm normalized name: biperiden 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 2 mg and 4 mg
Trial: 31151335
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) and dexmedetomidine (1 mcg/kg) - Group II
Trial: 31151335
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) - Group I
Trial: 19499659
Drug: TIVA-TCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA-TCI with propofol (Cpi = 4 microg/ml) and remifentanil
Trial: 17343103
Drug: New cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cardiovascular drugs without clinical trial outcome data
Trial: 17343103
Drug: Similar drugs
RxNorm normalized name: Antigonadotropins and similar agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar drugs with clinical trial outcome data
Trial: 9059545
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral losartan
Trial: 8198030
Drug: Transdermal nitroglycerin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin, 0.6 mg/hour
Trial: 10622071
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg b.d.
Trial: 3556123
Drug: Augmentin 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentin 375 mg t.d.s.
Trial: 3556123
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg t.d.s.
Trial: 26182747
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for peripheral vascular disease
Trial: 26182747
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for tibioperoneal lesions
Trial: 26182747
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for carotid lesions
Trial: 18977243
Drug: Tailored Internet-plus-email
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored Internet-plus-email intervention (access to a tailored website and weekly emails)
Trial: 31570509
Drug: Mass method
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass method of dosing epinephrine (milligrams per kilogram)
Trial: 31570509
Drug: Volume method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume method of dosing epinephrine (milliliters per kilogram)
Trial: 31570509
Drug: Mass method
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass method doses
Trial: 31570509
Drug: Volume method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume method doses
Trial: 17577112
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg hydrotalcite
Trial: 2886245
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg famotidine
Trial: 15726880
Drug: Itraconazole (Traconal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (Traconal 100 mg)
Trial: 9797644
Drug: Postprandial lipaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial lipaemia and post‐heparin LPL activity
Trial: 5443385
Drug: Intravenous pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentazocine 30 mg
Trial: 5443385
Drug: Intravenous pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentazocine 60 mg
Trial: 17214932
Drug: Non-Salvia miltiorrhiza
RxNorm normalized name: Salvia miltiorrhiza root extract
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Salvia miltiorrhiza treatment
Trial: 15019333
Drug: Control (observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (observation and laser treatment)
Trial: 11352445
Drug: Probenecid 500mg
RxNorm normalized name: PROBENECID 500MG TAB
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probenecid 500mg twice daily for 2 days before moxifloxacin
Trial: 9165133
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. infusion on day 1) and 5-fluorouracil (1000 mg/m2 continuous i.v. infusion for 120 hours) followed by radiotherapy (64-70 Gy in 2 Gy per fraction, 5 times/week)
Trial: 9165133
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (radiotherapy or radiotherapy followed by surgery)
Trial: 9165133
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy
Trial: 7970935
Drug: L-[2-15N]glutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-[2-15N]glutamine infusion
Trial: 7970935
Drug: L-[1-13C]leucine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-[1-13C]leucine infusion
Trial: 24595568
Drug: Topical clofibrate
RxNorm normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical clofibrate
Trial: 18245032
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus carbamazepine (10-30 mg/day plus 400-1200 mg/day)
Trial: 18245032
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus carbamazepine (400-1200 mg/day)
Trial: 11969360
Drug: Cefuroxime (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (100 mg/kg/day) IV
Trial: 11969360
Drug: Dicloxacillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicloxacillin (200 mg/kg/day) plus Chloramphenicol (100 mg/kg/day) IV
Trial: 12422059
Drug: Paroxetine (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-30 mg/day)
Trial: 10401446
Drug: Nortriptyline (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (adjusted to plasma concentration of 50-150 ng/ml)
Trial: 7240807
Drug: Subvirion influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subvirion influenza B vaccine (500 chick cell‐agglutinating units)
Trial: 7240807
Drug: Whole‐virus influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐virus influenza B vaccine
Trial: 7240807
Drug: Subvirion influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subvirion influenza B vaccine
Trial: 30591465
Drug: FOLFIRI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Trial: 30591465
Drug: mFOLFOX6 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Trial: 24433926
Drug: IFNβ‐1a i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ‐1a i.m. weekly injected (group a)
Trial: 24433926
Drug: IFNβ‐1a 44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ‐1a 44 μg s.c. injected three times a week (group b)
Trial: 19056572
Drug: FS50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS50 (50 g/day, 264 kcal)
Trial: 19056572
Drug: LP (maize-soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP (maize-soy flour, 71 g/day, 282 kcal)
Trial: 19056572
Drug: FS25 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS25 (25 g/day, 130 kcal)
Trial: 21934487
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser therapy (EVLT)
Trial: 16802211
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser therapy (EVLT) and Surgery
Trial: 29803534
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg (therapeutic dose)
Trial: 29803534
Drug: Nemonoxacin 750
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 750 mg (supratherapeutic dose)
Trial: 29803534
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg after high-fat food intake
Trial: 29803534
Drug: Nemonoxacin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (both doses)